Evidence map›Paper›PMID 37995040›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.

Mostafa Reda Mostafa, Mohamed Magdi Eid, Ahmed K Awad, Andrew Takla, Abdul Rhman Hassan, Basant E Katamesh, Majd M AlBarakat, Abdul Rhman Ziada, Sarah Mohamed, Karim M Al-Azizi and 1 more

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Mostafa Reda MostafaRochester Regional Health/Unity Hospital, Rochester, NY, USA. Moustafazaalouk33@gmail.com.
Mohamed Magdi EidRochester Regional Health/Unity Hospital, Rochester, NY, USA.
Ahmed K AwadFaculty of Medicine, Ain-Shams University, Cairo, Egypt.ORCID http://orcid.org/0000-0001-6647-1866
Andrew TaklaDepartment of Medicine, Rochester General Hospital, Rochester, NY, USA.
Abdul Rhman HassanFaculty of Medicine, Tanta University, Tanta, Egypt.
Basant E KatameshFaculty of Medicine, Tanta University, Tanta, Egypt.
Majd M AlBarakatFaculty of Medicine, Jordan University of Science and Technology, Amman, Jordan.
Abdul Rhman ZiadaFaculty of Medicine, Tanta University, Tanta, Egypt.
Sarah MohamedCairo university School of Medicine, Cairo, Egypt.
Karim M Al-AziziBaylor Scott and White Health-The Heart Hospital, Plano, TX, USA.
Andrew M GoldsweigDepartment of Cardiovascular Medicine, Baystate Medical Center, Springfield, MA, USA.
Tanta University · EGUnity Health System · USAin Shams University · EGBaystate Medical Center · USCairo University · EGHeart Hospital Baylor Plano · USJordan University of Science and Technology · JORochester General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCangrelor is a potent intravenous non-thienopyridine P2Y12 inhibitor. We conducted a network meta-analysis to study the efficacy and safety of cangrelor as compared with the oral P2Y12 inhibition, clopidogrel, or placebo in acute coronary syndromes.

methodsThis meta-analysis followed the Cochrane collaboration guidelines and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocols. Outcomes of interest included all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, major bleeding, minor bleeding, and the need for blood transfusion.

resultsThe analysis was comprised of 6 studies including 26,444 patients treated with cangrelor, clopidogrel, or placebo. There were no statistically significant differences in the incidence of all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, or major bleeding. Cangrelor was associated with a higher risk of minor bleeding than clopidogrel or placebo, with no difference in requiring blood transfusion.

conclusionCangrelor has comparable outcomes to clopidogrel in patients with acute coronary syndromes and can be used as a reliable alternative in this population.

Indexed as

Acute Coronary SyndromeMyocardial InfarctionPercutaneous Coronary InterventionThrombosisAdenosine MonophosphateClopidogrelHemorrhageHumansPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTreatment OutcomeAdenosine MonophosphatecangrelorClopidogrelPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Identifiers

PMID37995040
OpenAlexW4388941599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.